Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07505771 | A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer | EARLY_PHASE1 | RECRUITING | 105 | — | — | Apr 1, 2026 | Dec 1, 2034 | Apr 6, 2026 | 1 | United States |
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including adverse events (SAEs), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE criteria version 5.0, including SAEs, AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| 177Lu-IM-3050 | ACTIVE_COMPARATOR | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Name | Type | Description |
|---|---|---|
| 177Lu-IM-3050 | DRUG | 177Lu-IM-3050 is a FAP-directed radiopharmaceutical |
Inclusion Criteria: * ≥18 years of age * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2 * Histological or cytological diagnosis of a solid tumor * Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants mu...